Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
different colors or a completely different chemical structure than the company's FDA-approved medicine. In at least one instance, the product was nothing more than sugar alcohol, Eli Lilly said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback